Ticker Hub
INBX — AI Analysis & Sentiment
3 recent AI-generated analyses for INBX. Sentiment and confidence insights updated continuously.
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx reported promising interim Phase 2 clinical results for INBRX-106, significantly improving its development outlook for HNSCC. This de-risks...
May 11, 2026Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx's positive clinical update for Ozekibart in colorectal cancer and BLA submission for chondrosarcoma significantly de-risk its pipeline, cre...
Apr 21, 2026Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx's substantial full-year loss and increased debt burden from a new loan are key concerns for this clinical-stage biotech. The negative marke...
Mar 19, 2026